Already in VDRA treatment (aVDRA) | Starting VDRA treatment (VDRA+) | No VDRA treatment (VDRA-) | P | |
---|---|---|---|---|
N | 35 | 59 | 52 | |
Age (mean, range) | 59,4 (19–89) | 57,2 (19–86) | 65,1 (34–95)* | P < 0.05 |
Sex (% male) | 71 | 71 | 63 | Ns |
Diagnosis | ||||
Glomerulonephritis (n) | 6 | 14 | 9 | |
Tubulointerstitiel nephritis (n) | 1 | 1 | 1 | |
Pyeolonephritis (n) | 1 | 0 | 1 | |
Obstructive nephropathy (n) | 3 | 5 | 3 | |
Polycystic (ADPKD) (n) | 0 | 5 | 4 | |
Hypertensive (n) | 2 | 6 | 3 | |
DM type I (n) | 0 | 7 | 4 | |
DM type II (n) | 6 | 4 | 10 | |
Unknown (n) | 13 | 11 | 13 | |
Other (n) | 3 | 6 | 4 | |
Observation time (days) | ||||
Total | 17490 | 44282 | 30157 | P < 0.05 |
Median (range) | 500 (67–1603) | 751(84–1716) | 580 (93–1487) | P < 0.05 |
Kidney Function | ||||
eGFR (ml/min/1.73 m2) | 14.8 ± 5.8 | 16.5 ± 4.3 | 18.8 ± 10.9 | Ns |
Creatinine Clearance (ml/min) | 19.2 ± 6.5 | 21.7 ± 15.6 | 23.8 ± 15.8 | Ns |
U-Albumin (g/24 h) | 1.55 ± 1.96 | 1.96 ± 1.97 | 2.41 ± 2.32 | Ns |
Mineral-Bone | ||||
S-calcium (mmol/l) | 1.12 ± 0.11* | 1.17 ± 0.07 | 1.21 ± 0.08 | P < 0.001 |
S-phosphate (mmol/l) | 1.67 ± 0.50* | 1.45 ± 0.32 | 1.40 ± 0.32 | P < 0.005 |
S-PTH (pmol/l)* | 24.0 ± 16.0 | 21.3 ± 10.6 | 14.9 ± 10.1* | P < 0.005 |
Blood pressure | ||||
Systolic (mmHg) | 147 ± 19 | 151 ± 20 | 156 ± 20 | Ns |
Diastolic (mmHg) | 85 ± 13 | 85 ± 11 | 82 ± 11 | Ns |
Medication | ||||
Alfacalcidol (μg/week) | 3.0 ± 1.7 | |||
Calcium with Vitamin D (n,(%)) | 6 (17%) | 4 (7%) | 12 (23%) | Ns |
Phosphate-binder (n,(%)) | 9 (25%)* | 7 (12%) | 7 (13%) | P < 0.01 |
ACEi/ARB (n,(%)) | 21(60%)1 dual | 36 (61%)6 dual | 24 (46%) 3 dual | Ns |